TrialFrontiers in immunology2025

Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia.

Hui-Sheng Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.